PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
2.63
0.75–0.9x TRVN's 3.31. Bill Ackman might push for more working capital or better cash management.
2.63
0.75–0.9x TRVN's 3.31. Bill Ackman would recommend finding ways to boost near-cash assets or reduce short-term liabilities.
2.58
Cash Ratio 1.25–1.5x TRVN's 2.06. Bruce Berkowitz might see a strong liquidity buffer compared to the competitor.
No Data
No Data available this quarter, please select a different quarter.
-221.01
Both companies show negative short-term coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.